Critical Role of Human Bisphosphoglycerate Mutase Cys22 in the Phosphatase Activator-binding Site*

(Received for publication, December 23, 1996, and in revised form, February 24, 1997)

Pascale Ravel Dagger , Constantin T. Craescu §, Nicole Arous , Jean Rosa and Marie Claude Garel

From INSERM U.91, Hôpital Henri Mondor, 94010 Créteil, France and § INSERM U.350, Institut Curie, Centre Universitaire, 91405 Orsay, France

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSIONS
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES


ABSTRACT

The enzymatic activities catalyzed by bisphosphoglycerate mutase (BPGM, EC 5.4.2.4) have been shown to occur at a unique active site, with distinct binding sites for diphosphoglycerates and monophosphoglycerates. The physiological phosphatase activator (2-phosphoglycolate) binds to BPGM at an undetermined site.

BPGM variants were constructed by site-directed mutagenesis of three amino acid residues in the active site to identify residues specifically involved in the binding of the monophosphoglycerates and 2-phosphoglycolate. Substitution of Cys22 by functionally conservative residues, Thr or Ser, caused a great decrease in 2-phosphoglycolate-stimulated phosphatase activity and in the Ka value of the activator, whereas it caused no change in other catalytic activities or in the Km values of 2,3-diphosphoglycerate (2,3-DPG) and glycerate 3-phosphate (3-PG, EC 1.1.1.12), indicating that Cys22 is specifically involved either directly or indirectly in 2-phosphoglycolate binding.

Kinetic experiments showed that the Ka of the cofactor and the Km of 3-PG were affected by the substitution of Ser23 indicating that this residue is necessary for the fixation of both 3-PG and 2-phosphoglycolate. The R89K variant has previously been shown to have a modified Km value for monophosphoglycerates, however, its affinity for 2-phosphoglycolate is unaltered, suggesting that Arg89 is specifically involved in monophosphoglycerates binding.

CD spectroscopic studies of substrates and cofactor binding showed that 2,3-DPG induced structural modifications of normal and mutated enzymes which could be due to protein phosphorylation. Addition of 2-phosphoglycolate to phosphorylated proteins with normal affinity for the cofactor produced spectra with the same characteristics as unphosphorylated species.

In summary, monophosphoglycerates and 2-phosphoglycolate have partially distinct binding sites in human BPGM. The specific implication of the Cys22 residue in 2-phosphoglycolate binding is of great significance in the design of analogs of therapeutic benefit.


INTRODUCTION

The trifunctional bisphosphoglycerate mutase (BPGM, EC 5.4.2.4),1 first described by Rapoport and Luebering (1), regulates the level of 2,3-diphosphoglycerate (2,3-DPG) in human red blood cells via a main synthase activity and an additional phosphatase activity, leading to 2,3-DPG degradation (2, 3). The hydrolysis of 2,3-DPG is physiologically stimulated by 2-phosphoglycolate, a normal constituent of red blood cells (4). BPGM also displays a mutase reaction similar to that of the glycolytic enzyme monophosphoglycerate mutase (MPGM, EC 5.4.2.1) which reversibly converts glycerate 3-phosphate (3-PG) to glycerate 2-phosphate (5, 6).

In red blood cells, 2,3-DPG is the main allosteric effector of hemoglobin. It shifts the equilibrium between the oxy and deoxy conformations of hemoglobin by preferentially stabilizing the unliganded form (6). Consequently, increasing the level of 2,3-DPG would ameliorate oxygen delivery to the tissues. However, 2,3-DPG also promotes polymerization of deoxy-HbS in sickle cell disease (7), and so decreasing the level of 2,3-DPG would be of potential therapeutic advantage in this serious disease (8, 9). Modification of BPGM activity may enable the level of cellular 2,3-DPG to be varied.

The functional properties of the wild-type erythrocytic BPGM have been extensively studied (10). The three reactions have been shown to occur at a unique active site whereas distinct binding sites have been proposed for the two substrates: bisphosphoglycerates and monophosphoglycerates (11, 12). The amino acid sequence obtained from direct sequencing of the human protein (13) or deduced from cloned human (14), rabbit (15), and mouse BPGM cDNAs (16) shows extensive similarity with MPGM from different sources (17-19). The active site of yeast MPGM has been located using enzyme crystals soaked in the substrate, 3-PG (20). Although inactive enzyme was used in these studies, there is evidence indicating that 3-PG may interact with Ser11 and Thr20, two amino acid residues located in the putative active site.

Although human BPGM has been crystallized (21), x-ray diffraction analysis of the structure has not been obtained. We have constructed a three-dimensional model of human BPGM based on crystallographic data from yeast MPGM since in human BPGM and yeast MPGM about 50% of residues are identical (22). The BPGM model shows specific charge configuration near the postulated substrate position, in the active site, which differs from MPGM. In particular Ser11, Thr20, and Gly21 in yeast MPGM are replaced by Gly13, Cys22, and Ser23, respectively, in BPGM.

In an attempt to develop substrates or cofactor analogs of therapeutic benefit, BPGM variants were constructed by site-directed mutagenesis and the structure-function relationships of the enzymes were analyzed to determine which residues are critical in substrates or cofactor binding. A precise identification of mono- and diphosphoglycerate-binding sites would be of great benefit in the chemical synthesis of analogs capable of specifically modulating one of the three activities of BPGM. A prokaryotic expression vector constructed in our laboratory (23) was used to synthesize wild-type and mutant forms of BPGM in Escherichia coli. Analysis of the catalytic properties of variants have shown that Arg89 is specifically involved in the monophosphoglycerate-binding sites (24) as has been reported for a natural human BPGM variant (25-27). In contrast, we have shown that Gly13 is specifically involved in the diphosphoglycerate-binding sites and that replacement of Gly13 by a positively charged amino acid residue greatly activates the phosphatase reaction, whereas the synthase and mutase reactions are greatly reduced (28).

Further amino acid substitutions were made to determine which residues are actively involved in the catalytic reactions. Initially we focused on Cys22 as sulfhydryl treatment of human BPGM is known to inhibit the different catalytic activities to various degrees (29, 30). The position of Cys22, in the three-dimensional protein model appears to be in the putative active site (Fig. 1), strongly implicating it in the chemical inactivation.


Fig. 1. Ribbon drawing of the active site of human BPGM according to the three-dimensional model obtained by Craescu et al. (23). Cys22, Ser23, and Arg89 are positioned versus the 2 essential histidines of human BPGM.
[View Larger Version of this Image (74K GIF file)]

Second, mutagenesis experiments were performed targeting the Ser23 residue since Fothergill et al. (11) reported that the amide hydrogen of Ser23 in BPGM may interact with the hydroxyl function of 1,3-DPG and amino acid sequence comparisons indicate that Ser23 is conserved in BPGM from different sources but is not present in any MPGM.

The catalytic properties of several BPGM variants, obtained by substitution of Cys22 and Ser23 are reported here. Further enzymatic studies on the variant R89K described previously (24) are also reported. Circular dichroism spectroscopy was used to study modifications in the secondary structure of the purified proteins, both alone and in the presence of substrates or cofactor. The physical analyses were in agreement with the kinetic data. We conclude that there is at least a punctual discrimination between monophosphoglycerates and 2-phosphoglycolate-binding sites.


EXPERIMENTAL PROCEDURES

Materials

The buffer reagents were obtained from Merck (Darmstadt, Germany) except where specified otherwise. All substrates and commercial enzymes were from Boehringer Mannheim (Germany) except glyceraldehyde phosphate which was from Sigma. Trizma base (Tris), Gly-Gly buffer, 2-phosphoglycolate, Dowex 1W8-400, ampicillin, and isopropyl-beta -D-thiogalactoside were all from Sigma. [33P]Orthophosphoric acid was from Isotochim (France). Oligonucleotides for mutagenesis experiments were from Genset (France).

Methods

Site-directed Mutagenesis

The procedure for oligonucleotide-directed site-specific mutagenesis was based on the method of Taylor et al. (31) using the Sculptor kit developed by Amersham (United Kingdom). Single-stranded DNAs of putative mutant phages were prepared and sequenced using the dideoxy method (32). The Cys22 residue was replaced by Leu, Ser, or Thr by changing the BPGM cDNA sequence TGT (bases 177-179) to CTT, AGT, or ACT, respectively. The S23G mutation was constructed by changing the codon AGC (bases 180-183) to GGC. Expression plasmids were prepared as described previously (33) by subcloning the EcoRI/PstI fragment of the human BPGM mutated cDNA into the expression vector, pKK 223-3 (Pharmacia). The basic cloning methods described by Maniatis et al. (34) were used for all these procedures.

Production and Purification of Recombinant Proteins

Wild-type and mutant enzymes were prepared as described previously (33). The native and mutated enzymes were purified by an established procedure (23, 33), however, the lysate was not heated prior to chromatography and the first purification step was on an high pressure liquid chromatography column of Fractogel TSK-AF blue at room temperature (24). The purified enzymes were stored in sodium phosphate buffer containing 20% glycerol at -80 °C until used. Protein concentration was determined using the method of Lowry et al. (35). The purity of the enzymes was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described by Laemmli (36).

Synthase and Mutase Assays

Synthase activity was measured using a simplified method recently published (37). Mutase activity was measured as described previously (25). The catalytic constants of synthase and mutase activity were calculated using the epsilon  of NADH of 6 mM-1 cm-1 at 334 nm and by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program.

Phosphatase Assay

Phosphatase activity was measured using a radioactive procedure (37). Following the synthesis of the radioactive substrate [33P]2,3-DPG, the phosphatase reaction was monitored by measuring the radioactivity of monophosphorylated reaction products (Pi and 3-PG). Two types of phosphatase reaction were studied. The first was hydrolysis of 2,3-DPG in the presence of activator ions: chloride (100 mM) and phosphate (10 mM) (25). This reaction was called the ion-stimulated phosphatase activity. The second reaction was 2,3-DPG hydrolysis in the presence of both anions and the physiological activator 2-phosphoglycolate (50 µM). This reaction was called the 2-phosphoglycolate-stimulated phosphatase activity.

Circular Dichroism Spectroscopy

All far-UV CD spectra were recorded on a Jasco 700 spectropolarimeter in a 0.1-cm cell at 20 °C, at enzyme concentrations between 5 and 10 µM. Near-UV spectra were measured using 1-cm quartz cells at concentrations 10-fold higher. The average of 10 runs was taken corrected for solvent distortion. Samples were prepared in 10 mM sodium phosphate buffer at pH 7.0. The concentration of samples was determined from the UV absorption at 280 nm using epsilon  of the BPGM monomer of 50 mM-1 cm-1. The CD data are given as mean residue ellipticity in units of degree cm2 dmol-1.


RESULTS AND DISCUSSION

Purification of Wild-type and Mutant BPGMs Expressed in E. coli

In the human, murine, and rabbit BPGMs, the Cys22 and Ser23 residues are strictly conserved (Table I), however, at the position of Ser23 in BPGMs there is always a Gly in the MPGMs from human muscle and brain and from yeast. In contrast, whereas Cys22 is conserved in human muscle MPGM, it is substituted by Ser in human brain MPGM and by Thr in yeast MPGM. These two residues (Cys22 and Ser23) were replaced by amino acids found at the same position in different MPGMs by site-directed mutagenesis in E. coli. The following three mutated enzymes were synthesized: C22T, C22S, and S23G. The effect of the size of the side chain at position 22 was studied by constructing the C22L variant. The protein yield was the same for all the BPGM variants.

Table I. Alignment of the amino acid sequences (one-letter code) of the human BPGM, rabbit BPGM, murine BPGM, human MPGM type M (MPGM-M), human MPGM type B (MPGM-B), and yeast MPGM Residue numbers refer to the human BPGM amino acid sequence.


Enzyme Amino acid residues
21 22 23 24

Human BPGM F C S W
Rabbit BPGM F C S W
Murine BPGM F C S W
Human MPGM-M F C G W
Human MPGM-B F S G W
Yeast MPGM F T G W

Structural Integrity of the Enzymes

Circular dichroism experiments were conducted in near- and far-UV regions for all the purified enzymes, to detect aberrant protein folding or large-scale structural modifications induced by the amino acid substitutions.

The far-UV circular dichroism spectrum (185-250 nm) is a sensitive probe for protein secondary structure. The wild-type spectrum is characterized by two negative peaks at 208 and 222 nm and by a positive one at 192 nm (Fig. 2A). The relative intensities of these peaks and the global shape of the spectrum are characteristic for alpha /beta protein three-dimensional structure (38). The amplitude of the negative peak at 222 nm is directly related to the structure of the alpha -helix. The mutants analyzed in this study (C22L, C22T, C22S, S23G, and R89K) all had similar CD spectra (data not shown), suggesting that the secondary structure was not significantly perturbed by the amino acid substitutions.


Fig. 2. Circular dichroism spectra of wild-type BPGM. Molecular ellipcities in the far-UV region (A) and near-UV CD signal (B) are plotted versus wavelength.
[View Larger Version of this Image (13K GIF file)]

The near-UV CD spectrum (250-300 nm) gives a qualitative measure of changes in tertiary structure as it is sensitive to assymetry of aromatic side chains (Trp, Tyr, and Phe). All the variants had similar near-UV spectra to the wild-type BPGM (Fig. 2B).

The enzymes studied here were found to be stable in solution under the experimental conditions used. Taken together with the CD results, this strongly suggested that the secondary and global tertiary structure of the mutant enzymes was unaltered by the amino acid substitutions. The alterations in enzyme activity are therefore likely to be due to the local changes induced by specific amino acid substitutions.

Functional Analysis

The Michaelis constants were determined for each substrate. In addition, the affinity constant for 2-phosphoglycolate was also determined (Tables II, III, IV). A detailed analysis of all the catalytic activities enabled the functions of Cys22, Ser23, and Arg89 in monophosphoglycerates and phosphatase activator binding to be distinguished.

Table II. Steady-state kinetic parameters of synthase activity of wild-type and mutant forms of BPGM

kcat, the rate constant for 2,3-DPG synthesis, equal to NADH reduction at saturating 3-PG and GAP concentrations, was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of NAD reduced per second per mole of enzyme. The error given for kcat/Km was calculated from the sum of relative errors on values in the numerator and denominator. Results are the average of independent series of experiments. kcat, the rate constant for 2,3-DPG synthesis, equal to NADH reduction at saturating 3-PG and GAP concentrations, was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of NAD reduced per second per mole of enzyme. The error given for kcat/Km was calculated from the sum of relative errors on values in the numerator and denominator. Results are the average of independent series of experiments.

Enzyme kcat Km 3-PGa kcat/Km

s-1 mM s-1 mM-1
WT 13.63  ± 0.30 28.70  ± 0.90 0.47  ± 0.02
C22T 8.48  ± 0.85 23.86  ± 4.03 0.36  ± 0.10
C22S 9.94  ± 0.91 20.98  ± 0.93 0.47  ± 0.06
S23G 4.63  ± 0.19 51.90  ± 5.20 0.09  ± 0.01

a 3-PG as substrate.

Table III. Steady-state kinetic parameters of mutase activity of wild-type and mutant forms of BPGM

kcat, the rate constant for 2-PG apparition, equal to NADH oxidation during the last step of enzymatic cascade allowing transformation of 2-PG at saturating substrates concentrations, was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of NADH oxidized per second per mole of BPGM. The error given for kcat/Km was calculated as explained in Table II. kcat, the rate constant for 2-PG apparition, equal to NADH oxidation during the last step of enzymatic cascade allowing transformation of 2-PG at saturating substrates concentrations, was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of NADH oxidized per second per mole of BPGM. The error given for kcat/Km was calculated as explained in Table II.

Enzyme kcat Kma 2,3-DPG Kmb 3-PG kcat/Km 2,3-DPG kcat/Km 3-PG

s-1 mM s-1 mM-1
WT 13.33  ± 0.89 0.300  ± 0.034 0.071  ± 0.007 44.43  ± 8.00 187.75  ± 31.31
C22T 7.89  ± 0.51 0.583  ± 0.200 0.059  ± 0.006 13.53  ± 5.52 133.73  ± 22.24
C22S 22.43  ± 1.44 0.281  ± 0.162 0.056  ± 0.009 79.82  ± 5.14 400.53  ± 90.08
S23G 30.40  ± 1.78 0.182  ± 0.018 0.207  ± 0.027 167.03  ± 26.30 146.86  ± 27.75

a Determined with different concentrations of 2,3-DPG substrate.
b Determined with different concentrations of 3-PG substrate.

Table IV. Steady-state kinetic parameters of phosphatase activity of wild-type and mutant forms of BPGM

kcat, the rate constant for 2,3-DPG hydrolysis at a saturating substrate concentration proportional to monophosphorylated products (3-PG and Pi) was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of 2,3-DPG hydrolyzed per second per mole of BPGM. The error given for kcat/Km was calculated as explained in Table II. kcat, the rate constant for 2,3-DPG hydrolysis at a saturating substrate concentration proportional to monophosphorylated products (3-PG and Pi) was obtained by fitting experimental points to the Michaelis-Menten equation with a nonlinear iterative regression program. It is expressed in moles of 2,3-DPG hydrolyzed per second per mole of BPGM. The error given for kcat/Km was calculated as explained in Table II.

Enzyme Ion stimulated phosphatase activitya
2-Phosphoglycolate-stimulated phosphatase activityb
kcat Km 2,3-DPG kcat/Km kcat Kmc 2,3-DPG kcat/Km Ka 2-phosphoglycolate

min-1 µM min-1M-1 min-1 µM min-1 µM-1 mM
WT 0.75  ± 0.06 51.91  ± 1.60 0.0144  ± 0.0016 39.00  ± 1.55 24.98  ± 2.70 1.56  ± 0.23 0.084  ± 0.016
C22T 0.46  ± 0.06 32.88  ± 6.35 0.0140  ± 0.0045 2.78  ± 0.23 20.48  ± 3.40 0.136  ± 0.034 1.900  ± 0.160
C22S 0.80  ± 0.05 40.40  ± 1.00 0.0198  ± 0.0017 7.67  ± 0.55 29.41  ± 5.65 0.261  ± 0.069 1.312  ± 0.209
S23G 0.84  ± 0.05 61.88  ± 16.64 0.0136  ± 0.0045 13.98  ± 1.31 22.87  ± 0.45 0.611  ± 0.070 0.339  ± 0.046
R89K 1.08  ± 0.07 49.51  ± 6.77 0.0218  ± 0.0044 43.92  ± 3.75 NDc ND 0.054  ± 0.007

a Reaction occurred in the presence of 10 mM KH2PO4 and 100 mM KCl.
b Reaction occurred in the presence of 10 mM KH2PO4, 100 mM KCl, and 50 µM 2-phosphoglycolate.
c ND, not determined in this study but already published (24).

Cys22 Is Specifically Involved in 2-Phosphoglycolate Binding

When Cys22 was substituted by Ser, a polar residue of similar size, only the 2-phosphoglycolate-stimulated phosphatase reaction was significantly reduced (Tables II, III, IV). The presence of another polar residue (Thr) in this position caused an additional decrease in cofactor-stimulated phosphatase reaction, indicating that residue 22 and its specific polarity are important in this catalytic activity. An increase in the size of the side chain from Ser to Thr caused a moderate alteration of all the activities (Tables II, III, IV), suggesting that the bulkier moiety reduced enzymatic activity. This supposition was reinforced by the functional analysis of the C22L variant which had lost all catalytic activities (data not shown), probably due to the large size of the leucine side chain.

Further analysis of the catalytic reaction parameters may facilitate an understanding of the molecular basis of the reactions. The steady-state kinetic parameters of the synthase, mutase, and ion-stimulated phosphatase activities were not significantly altered in C22S and C22T (Tables II, III, IV), whereas the affinity for 2-phosphoglycolate was drastically reduced, with Ka values 22-fold higher for C22T, and 16-fold higher for C22S than for the wild-type enzyme (Table IV). In contrast, the Km values for 2,3-DPG and 3-PG of the Cys22-mutated enzyme was not significantly altered.

The enzymatic data provides good evidence that Cys22 is necessary for 2-phosphoglycolate-stimulated phosphatase activity probably via activator binding. These results are consistent with those of Diederich et al. (39) who reported that the phosphatase reaction of yeast MPGM which has a Thr side chain at position 22, was not activated by 2 mM 2-phosphoglycolate, whereas this catalytic activity was stimulated 9-fold in MPGM from human skeletal muscle, which has a Cys residue in the position corresponding to Cys22 in human BPGM. Furthermore, MPGM from human erythrocytes (brain type) which has a serine residue at position 22, has very little phosphatase activity, even in the presence of 1 mM 2-phosphoglycolate (40), indicating the lack of activation by this cofactor.

Our results, in agreement with Hg2+-inhibition experiments on BPGM activities (30), did not implicate Cys22 in 2,3-DPG binding, indicating that cysteine oxidation did not impede this binding. All the data support the conclusion that Cys22 is specifically involved, directly or indirectly, in 2-phosphoglycolate binding of human BPGM.

Ser23 Is Involved in the Binding of Both Monophosphoglycerates and 2-Phosphoglycolate

The properties of the S23G variant were very similar to MPGM: the mutase activity was highly effective whereas the synthase reaction was significantly reduced (Tables II, III, IV). Substitution of Ser by Gly did not affect either of the 2,3-DPG hydrolysis reactions whereas 2-phosphoglycolate stimulated activity was greatly reduced.

A detailed analysis of the catalytic reactions indicated a 3-fold increase in the Michaelis constant for 3-PG in the mutase reaction and a 4-fold decrease in the affinity for 2-phosphoglycolate in the cofactor stimulated phosphatase reaction, however, no significant modification of the apparent affinity for 2,3-DPG was observed as provided by absence of its Km modification (Tables II, III, IV).

Two other proteins, mutated at position 23 were also studied. The kinetics showed that the replacement of Ser23 by Ala did not produce any significant change in the enzymatic reactions, however a variant with a Thr residue at position 23 was too unstable to be studied (data not shown).

These enzymatic results all provide strong evidence for a direct or indirect active role of Ser23 in 3-PG and 2-phosphoglycolate binding. The presence of a glycine residue at position 23 as in all MPGM species, may explain the increase in mutase activity.

Arg89 Is Specifically Involved in the Monophosphoglycerate-binding Site

Previous results obtained in our laboratory strongly suggested that the Arg89 residue of human BPGM is specifically involved in the 3-PG-binding site (24, 27). We completed the functional studies on the R89K mutant by investigating the ion-stimulated phosphatase activity and measuring the affinity constant for 2-phosphoglycolate. This substitution has no significant effect on the catalytic constant or the activator affinity (Table IV).

As previously reported (24), the R89K mutated protein presents increased Michaelis constants for monophosphoglycerates, whereas the 2,3-DPG one is not affected. Our present results demonstrated that its affinity for 2-phosphoglycolate was also unchanged, indicating that Arg89 is only involved, directly or indirectly, in the monophosphoglycerate-binding sites. By these properties Arg89 allows a discrimination between monophosphoglycerates and 2-phosphoglycolate-binding sites.

CD Spectroscopic Investigation of the Substrates and Cofactor Binding

The far-UV region of the CD spectrum was used to monitor possible structural changes of the enzymes upon ligand binding. Addition of 2,3-DPG to the native BPGM solution (protein monomer: 2,3-DPG molar ratio = 1:10) induced spectroscopic changes. A small but significant and reproducible decrease in the negative band at 208 nm was detected, whereas the alpha -helix-type band at 222 nm was practically unchanged (Fig. 3). Phosphorylation of the protein by 2,3-DPG is thought to be the first step in the mutase and phosphatases activities of BPGM (11) and CD spectral modification may be a result of this phosphorylation. The lack of resolution of the method precludes a precise structural explanation of the decrease in the 208 nm negative band, however, the observation is compatible with a relative decrease in the random coil spectral component (negative band at 197 nm) in favor of more regular structures. The stabilization of the COOH-terminal structure of the enzyme by 2,3-DPG fixation and subsequent phosphorylation (11) would explain the spectroscopic data. Similar CD experiments with yeast MPGM failed to detect any effect of 2,3-DPG (41). This may be due to differences between the COOH-terminal structures of MPGM and BPGM.


Fig. 3. Circular dichroism spectra of wild-type BPGM in presence of 2,3-DPG. Molecular ellipticity is plotted versus wavelength for wild-type enzyme in absence of any substrate (---) or in presence of 100 µM 2,3-DPG (- - -).
[View Larger Version of this Image (14K GIF file)]

Similar results were obtained for the C22S, C22T, S23G, and R89K variants probably due to their comparable binding parameters for 2,3-DPG. Monophosphoglycerate alone and 2-phosphoglycolate alone did not produce any spectroscopic modification.

The addition of 2-phosphoglycolate to the phosphorylated wild-type and R89K mutant led to restoration of the spectroscopic characteristics of the unmodified enzymes (Fig. 4). Structurally, this may correspond to dephosphorylation of the enzyme after stimulation of its phosphatase activity by the cofactor. This hypothesis is further supported by the fact that the two phosphorylated variants, S23G and C22T, which have lower 2-phosphoglycolate affinity than the wild-type and decreased cofactor-stimulated phosphatase activity, show no additional CD modification in the presence of the cofactor.


Fig. 4. Effect of 2-phosphoglycolate addition on circular dichroism spectra of enzymes already modified by 2,3-DPG. A molecular ellipticity versus wavelength for wild-type enzyme in absence of any substrate (---), in the presence of 100 µM 2,3-DPG alone (- - -) or after subsequent addition of 10 µM (···) or 110 µM (- - -) 2-phosphoglycolate in enzyme solution previously modified by 100 µM 2,3-DPG.
[View Larger Version of this Image (16K GIF file)]

In contrast, addition of 3-PG to the phosphorylated native and mutated BPGMs did not produce a significant spectral change, probably because the enzymes maintain the phosphorylated state. The presence of 3-PG induces the mutase activity without any reduction in the 2,3-DPG level. Under these conditions, the transient phosphorylated state of the enzymes may be maintained.


CONCLUSIONS

The present results show that monophosphoglycerates and 2-phosphoglycolate have partially distinct binding sites in the active site of BPGM. Cys22 is involved specifically, either directly or indirectly, in 2-phosphoglycolate binding, whereas Arg89 is specific for 3-PG binding, demonstrating that the binding sites are distinct. On the other hand, Ser23 seems to be implicated in both binding sites. Delineation of the specific roles of amino acid residues in the active site is of great importance in the design of substrate or cofactor analogs of potential pharmacological benefit. Analogs of 2-phosphoglycolate modulating the 2,3-DPG level in red blood cells, without changing 3-PG binding, would be of great therapeutic advantage. Discrimination between the monophosphoglycerates and 2-phosphoglycolate-binding sites also prevents perturbation of red blood cells MPGM activity by avoiding cofactor analogs affecting the 3-PG-binding site. This is a critical requirement in therapeutic design since the integrity of MPGM and its interaction with 3-PG in the glycolysis, is critical for cell survival.


FOOTNOTES

*   This work was supported in part by grants from the Institut National de la Santé et de la Recherche Medicale (INSERM Unité 91) and the Glaxo Wellcome group.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Recipient of fellowships from Glaxo Wellcome group.
   To whom correspondence should be addressed: Hôpital Henri Mondor, INSERM U.91 94010 Créteil, France. Tel.: 33-1-49-81-28-51; Fax: 33-1-49-81-28-95.
1   The abbreviations used are: BPGM, bisphosphoglycerate mutase; MPGM, monophosphoglycerate mutase; 2,3-DPG, 2,3-diphosphoglycerate; 3-PG, glycerate 3-phosphate; 1,3-DPG, glycerate 1,3-diphosphate; 2-PG, glycerate 2-phosphate.

ACKNOWLEDGEMENT

We thank Raymonde Lameynardie for many helpful suggestions during the course of this work.


REFERENCES

  1. Rapoport, S., and Luebering, J. (1950) J. Biol. Chem. 183, 507-516 [Free Full Text]
  2. Rose, Z. B. (1968) J. Biol. Chem. 243, 4810-4820 [Abstract/Free Full Text]
  3. Rose, Z. B., and Whalen, R. G. (1973) J. Biol. Chem. 248, 1513-1519 [Abstract/Free Full Text]
  4. Rose, Z. B., and Liebowitz, J. (1970) J. Biol. Chem. 245, 3232-3241 [Abstract/Free Full Text]
  5. Rosa, R., Gaillardon, J., and Rosa, J. (1973) Biochem. Biophys. Res. Commun. 51, 536-542 [Medline] [Order article via Infotrieve]
  6. Sasaki, R., Ikura, K., Sugimoto, E., and Chiba, H. (1975) Eur. J. Biochem 50, 581-593 [Abstract]
  7. May, A., and Huehns, E. R. (1975) Br. J. Haematol. 30, 317-335 [Medline] [Order article via Infotrieve]
  8. Poillon, W. N., and Kim, B. C. (1990) Blood 76, 1028-1036 [Abstract]
  9. Poillon, W. N., Kim, B. C., Labotka, R. J., Hicks, C. U., and Kark, J. A. (1995) Blood 85, 3289-3296 [Abstract/Free Full Text]
  10. Rose, Z. B. (1980) in Advances in Enzymology (Meister, A., ed), Vol. 51, pp. 211-253, Academic Press, New York [Medline] [Order article via Infotrieve]
  11. Fothergill-Gilmore, L. A., and Watson, H. C. (1989) in Advances in Enzymology (Meister, A., ed), Vol. 62, pp. 227-313, John Wiley and Sons, New York [Medline] [Order article via Infotrieve]
  12. Chiba, H., and Sasaki, R. (1978) Curr. Top. Cell. Regul. 14, 75-116 [Medline] [Order article via Infotrieve]
  13. Haggarty, N. W., Dunbar, B., and Fothergill, L. A. (1983) EMBO J. 2, 1213-1220 [Medline] [Order article via Infotrieve]
  14. Joulin, V., Peduzzi, J., Romeo, P. H., Rosa, R., Valentin, C., Dubart, A., Lapeyre, B., Blouquit, Y., Garel, M. C., Goossens, M., Rosa, J., and Cohen-Solal, M. (1986) EMBO J. 5, 2275-2283 [Abstract]
  15. Yanagawa, S., Hitomi, K., Sasaki, R., and Chiba, H. (1986) Gene (Amst.) 44, 185-191 [Medline] [Order article via Infotrieve]
  16. Le Boulch, P., Joulin, V., Garel, M. C., Rosa, J., and Cohen-Solal, M. (1988) Biochem. Biophys. Res. Commun 156, 874-881 [Medline] [Order article via Infotrieve]
  17. White, M. F., and Fothergill-Gilmore, L. A. (1988) FEBS Lett. 229, 383-387 [CrossRef][Medline] [Order article via Infotrieve]
  18. Shanske, S., Sakoda, S., Hermodson, M. A., DiMauro, S., and Schon, E. A. (1987) J. Biol. Chem 262, 14612-14617 [Abstract/Free Full Text]
  19. Blouquit, Y., Calvin, M.-C., Rosa, R., Promé, D., Promé, J.-C., Pratbernou, F., Cohen-Solal, M., and Rosa, J. (1988) J. Biol. Chem. 263, 16906-16910 [Abstract/Free Full Text]
  20. Winn, S. I., Watson, H. C., Harkins, R. N., and Fothergill, L. A. (1981) Philos. Trans. R. Soc. Ser. B 293, 121-130 [Medline] [Order article via Infotrieve]
  21. Cherfils, J., Rosa, R., Garel, M. C., Calvin, M. C., Rosa, J., and Janin, J. (1991) J. Mol. Biol. 218, 269-270 [Medline] [Order article via Infotrieve]
  22. Craescu, C. T., Schaad, O., Garel, M. C., Rosa, R., and Edelstein, S. (1992) Biochimie (Paris) 74, 519-526 [Medline] [Order article via Infotrieve]
  23. Calvin, M. C., Blouquit, Y., Garel, M. C., Préhu, M. O., Cohen-Solal, M., Rosa, J., and Rosa, R. (1990) Biochimie (Paris) 72, 337-343 [Medline] [Order article via Infotrieve]
  24. Garel, M. C., Lemarchandel, V., Calvin, M.-C., Arous, N., Craescu, C. T., Préhu, M. O., Rosa, J., and Rosa, R. (1993) Eur. J. Biochem. 213, 493-500 [Abstract]
  25. Rosa, R., Préhu, M. O., Beuzard, Y., and Rosa, J. (1978) J. Clin. Invest. 62, 907-915 [Medline] [Order article via Infotrieve]
  26. Rosa, R., Préhu, M. O., Albrecht-Ellmer, K., and Calvin, M. C. (1983) Biochim. Biophys. Acta 742, 243-249 [Medline] [Order article via Infotrieve]
  27. Rosa, R., Blouquit, Y., Calvin, M. C., Promé, D., Promé, J.-C., and Rosa, J. (1989) J. Biol. Chem. 264, 7837-7843 [Abstract/Free Full Text]
  28. Garel, M. C., Arous, N., Calvin, M. C., Craescu, C. T., Rosa, J., and Rosa, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3593-3597 [Abstract/Free Full Text]
  29. Rosa, R., and Calvin, M. C. (1988) Biochem. Biophys. Res. Commun. 153, 945-951 [Medline] [Order article via Infotrieve]
  30. Tauler, A., Bartrons, R., Pons, G., and Carreras, J. (1983) Comp. Biochem. Physiol. B 76, 789-793 [Medline] [Order article via Infotrieve]
  31. Taylor, J. W., Ott, J., and Eckstein, F. (1985) Nucleic Acids Res. 13, 8765-8785 [Abstract]
  32. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467 [Abstract]
  33. Garel, M.-C., Joulin, V., Le Boulch, P., Calvin, M.-C., Prehu, M.-O., Arous, N., Longin, R., Rosa, R., Rosa, J., and Cohen-Solal, M. (1989) J. Biol. Chem. 264, 18966-18972 [Abstract/Free Full Text]
  34. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  35. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  36. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  37. Ravel, P., Garel, M. C., and Toullec, D. (1997) C. R. Acad. Sci. Paris III 320, 27-33 [Medline] [Order article via Infotrieve]
  38. Johnson, W. C., Jr. (1990) Proteins 7, 205-214 [Medline] [Order article via Infotrieve]
  39. Diederich, D., Khen, A., Santos, I., and Grisolia, S. (1970) Biochim. Biophys. Acta 212, 441-449 [Medline] [Order article via Infotrieve]
  40. Rosa, R., Calvin, M. C., Prehu, M. O., and Arous, N. (1984) J. Chromatogr. 285, 203-209 [CrossRef][Medline] [Order article via Infotrieve]
  41. White, M. F., Fothergill-Gilmore, L. A., Kelly, S. M., and Price, N. C. (1993) Biochem. J. 291, 479-483 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.